{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:42:50Z","timestamp":1790091770444,"version":"4.0.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["F31DA054752"],"award-info":[{"award-number":["F31DA054752"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA052214"],"award-info":[{"award-number":["R01DA052214"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01DA048174"],"award-info":[{"award-number":["K01DA048174"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA052214"],"award-info":[{"award-number":["R01DA052214"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UH3DA044822"],"award-info":[{"award-number":["UH3DA044822"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA052214"],"award-info":[{"award-number":["R01DA052214"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Over the past decade in the USA, increases in overdose rates of cocaine and psychostimulants with opioids were highest among Black, compared to White, populations. Whether fentanyl has contributed to the rise in cocaine and psychostimulant overdoses in Ohio is unknown. We sought to measure the impact of fentanyl on cocaine and psychostimulant overdose death rates by race in Ohio.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted time series and spatiotemporal analyses using data from the Ohio Public Health Information Warehouse. Primary outcomes were state- and county-level overdose death rates from 2010 to 2020 for Black and White populations. Measures of interest were overdoses consisting of four drug involvement classes: (1) all cocaine overdoses, (2) cocaine overdoses not involving fentanyl, (3) all psychostimulant overdoses, and (4) psychostimulant overdoses not involving fentanyl. We fit a time series model of log standardized mortality ratios (SMRs) using a Bayesian generalized linear mixed model to estimate posterior median rate ratios (RR). We conducted a spatiotemporal analysis by modeling the SMR for each drug class at the county level to characterize county-level variation over time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In 2020, the greatest overdose rates involved cocaine among Black (24.8 deaths\/100,000 people) and psychostimulants among White (10.1 deaths\/100,000 people) populations. Annual mortality rate ratios were highest for psychostimulant-involved overdoses among Black (aRR\u2009=\u20091.71; 95% CI (1.43, 2.02)) and White (aRR\u2009=\u20091.60, 95% CI (1.39, 1.80)) populations. For cocaine not involving fentanyl, annual mortality rate ratios were similar among Black (aRR\u2009=\u20091.04; 95% CI (0.96,1.16)) and White (aRR\u2009=\u20091.02; 95% CI (0.87, 1.20)) populations. Within each drug category, change over time was similar for both racial groups. The spatial models highlighted county-level variation for all drug categories.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Without the involvement of fentanyl, cocaine overdoses remained constant while psychostimulant overdoses increased. Tailored harm reduction approaches, such as distribution of fentanyl test strips and the removal of punitive laws that influence decisions to contact emergency services, are the first steps to reduce cocaine overdose rates involving fentanyl among urban populations in Ohio. In parallel, harm reduction policies to address the increase in psychostimulant overdoses are warranted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-00936-9","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T09:02:27Z","timestamp":1705482147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The impact of fentanyl on state- and county-level psychostimulant and cocaine overdose death rates by race in Ohio from 2010 to 2020: a time series and spatiotemporal analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Angela T.","family":"Estadt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian N.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JaNelle M.","family":"Ricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Lancaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staci","family":"Hepler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"key":"936_CR1","unstructured":"Centers for Disease Control and Prevention National Center for Health Statistics: National Vital Statistics System, Mortality 1999\u20132020 on CDC WONDER Online Database, released in 2021. 2023."},{"key":"936_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","volume":"34","author":"D Ciccarone","year":"2021","unstructured":"Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34:344\u201350.","journal-title":"Curr Opin Psychiatry"},{"key":"936_CR3","unstructured":"NIDA: Fentanyl DrugFacts. 2021."},{"key":"936_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103791","volume":"107","author":"A Ivsins","year":"2022","unstructured":"Ivsins A, Fleming T, Barker A, Mansoor M, Thakarar K, Sue K, McNeil R. The practice and embodiment of \u201cgoofballs\u201d: a qualitative study exploring the co-injection of methamphetamines and opioids. Int J Drug Policy. 2022;107: 103791.","journal-title":"Int J Drug Policy"},{"key":"936_CR5","doi-asserted-by":"crossref","unstructured":"Baker R, Leichtling G, Hildebran C, Pinela C, Waddell EN, Sidlow C, Leahy JM, Korthuis PT. \"Like Yin and Yang\": perceptions of methamphetamine benefits and consequences among people who use opioids in rural communities. J Addict Med. 2020.","DOI":"10.1097\/ADM.0000000000000669"},{"key":"936_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.824940","volume":"13","author":"BD Rhed","year":"2022","unstructured":"Rhed BD, Harding RW, Marks C, Wagner KT, Fiuty P, Page K, Wagner KD. Patterns of and rationale for the co-use of methamphetamine and opioids: findings from qualitative interviews in New Mexico and Nevada. Front Psychiatry. 2022;13: 824940.","journal-title":"Front Psychiatry"},{"key":"936_CR7","doi-asserted-by":"crossref","unstructured":"Valente PK, Bazzi AR, Childs E, Salhaney P, Earlywine J, Olson J, Biancarelli DL, Marshall BDL, Biello KB. Patterns, contexts, and motivations for polysubstance use among people who inject drugs in non-urban settings in the U.S. Northeast. Int J Drug Policy 2020; 85:102934.","DOI":"10.1016\/j.drugpo.2020.102934"},{"key":"936_CR8","doi-asserted-by":"crossref","unstructured":"Townsend T, Kline D, Rivera-Aguirre A, Bunting AM, Mauro PM, Marshall BDL, Martins SS, Cerd\u00e1 M. Racial\/Ethnic and Geographic Trends in Combined Stimulant\/Opioid Overdoses, 2007\u20132019. Am J Epidemiol 2022.","DOI":"10.1093\/aje\/kwab290"},{"key":"936_CR9","doi-asserted-by":"crossref","unstructured":"Scott MC, Wahl OF. Substance Abuse Stigma and Discrimination Among African American Male Substance Users. In.; 2011","DOI":"10.5463\/sra.v1i1.3"},{"key":"936_CR10","unstructured":"Washington HA. Medical apartheid : the dark history of medical experimentation on Black Americans from colonial times to the present. 1st ed edn. New York: Doubleday; 2006."},{"key":"936_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108867","volume":"226","author":"S Mantha","year":"2021","unstructured":"Mantha S, Nolan ML, Harocopos A, Paone D. Racial disparities in criminal legal system involvement among New York City overdose decedents: implications for diversion programs. Drug Alcohol Depend. 2021;226: 108867.","journal-title":"Drug Alcohol Depend"},{"key":"936_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12954-021-00564-7","volume":"18","author":"C Daniels","year":"2021","unstructured":"Daniels C, Aluso A, Burke-Shyne N, Koram K, Rajagopalan S, Robinson I, Shelly S, Shirley-Beavan S, Tandon T. Decolonizing drug policy. Harm Reduct J. 2021;18:120.","journal-title":"Harm Reduct J"},{"key":"936_CR13","unstructured":"Center for Behavioral Health Statistics and Quality. Racial\/ethnic differences in substance use, substance use disorders, and substance use treatment utilization among people aged 12 or older (2015\u20132019). Substance Abuse and Mental Health Services Administration ed. Rockville, MD; 2021."},{"key":"936_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s11414-018-9586-y","volume":"45","author":"A Acevedo","year":"2018","unstructured":"Acevedo A, Panas L, Garnick D, Acevedo-Garcia D, Miles J, Ritter G, Campbell K. Disparities in the treatment of substance use disorders: does where you live matter? J Behav Health Serv Res. 2018;45:533\u201349.","journal-title":"J Behav Health Serv Res"},{"key":"936_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102704","volume":"85","author":"EL Richard","year":"2020","unstructured":"Richard EL, Schalkoff CA, Piscalko HM, Brook DL, Sibley AL, Lancaster KE, Miller WC, Go VF. \u201cYou are not clean until you\u2019re not on anything\u201d: perceptions of medication-assisted treatment in rural Appalachia. Int J Drug Policy. 2020;85: 102704.","journal-title":"Int J Drug Policy"},{"key":"936_CR16","unstructured":"Meit M, Knudson A, Gilbert T, Yu ATC, Tanenbaum E, TenBroeck S, Bayne A, Popat S. The 2014 Update of the Rural-Urban Chartbook. Center RHRPR ed: Rural Health Reform Policy Research Center; 2014."},{"key":"936_CR17","unstructured":"Dombrowski K, Crawford D, Khan B, Tyler K. Current rural drug use in the US Midwest. J Drug Abuse 2016, 2."},{"key":"936_CR18","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1080\/10826084.2021.1887248","volume":"56","author":"CA Schalkoff","year":"2021","unstructured":"Schalkoff CA, Richard EL, Piscalko HM, Sibley AL, Brook DL, Lancaster KE, Miller WC, Go VF. \u201cNow We Are Seeing the Tides Wash In\u201d: trauma and the opioid epidemic in rural Appalachian Ohio. Subst Use Misuse. 2021;56:650\u20139.","journal-title":"Subst Use Misuse"},{"key":"936_CR19","unstructured":"National Drug Intelligence Center U.S. Department of justice: Ohio high intensity drug trafficking area. In Drug Market Analysis; 2008."},{"key":"936_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107779","volume":"208","author":"D Rosenblum","year":"2020","unstructured":"Rosenblum D, Unick J, Ciccarone D. The rapidly changing US illicit drug market and the potential for an improved early warning system: evidence from Ohio Drug crime labs. Drug Alcohol Depend. 2020;208: 107779.","journal-title":"Drug Alcohol Depend"},{"key":"936_CR21","unstructured":"U.S. Census Bureau: Ohio Data Profile. 2020."},{"key":"936_CR22","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2105\/AJPH.2023.307337","volume":"113","author":"D Kline","year":"2023","unstructured":"Kline D, Bunting AM, Hepler SA, Rivera-Aguirre A, Krawczyk N, Cerda M. State-level history of overdose deaths involving stimulants in the United States, 1999\u20132020. Am J Public Health. 2023;113:991\u20139.","journal-title":"Am J Public Health"},{"key":"936_CR23","unstructured":"Ohio Public Health Information Warehouse [https:\/\/publicapps.odh.ohio.gov\/EDW\/DataCatalog]."},{"key":"936_CR24","unstructured":"Ohio Public Health Information Warehouse, Frequently Asked Questions [https:\/\/publicapps.odh.ohio.gov\/EDW\/Faq]."},{"key":"936_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/EDE.0000000000001299","volume":"32","author":"D Kline","year":"2021","unstructured":"Kline D, Pan Y, Hepler SA. Spatiotemporal trends in opioid overdose deaths by race for counties in Ohio. Epidemiology. 2021;32:295\u2013302.","journal-title":"Epidemiology"},{"key":"936_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11904-018-0398-8","volume":"15","author":"K Johnson","year":"2018","unstructured":"Johnson K, Jones C, Compton W, Baldwin G, Fan J, Mermin J, Bennett J. Federal response to the opioid crisis. Curr HIV\/AIDS Rep. 2018;15:293\u2013301.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"936_CR27","volume-title":"Opioid overdose","author":"E Schiller","year":"2022","unstructured":"Schiller E, Goyal A, Mechanic O. Opioid overdose. Treasure Island: StatPearls Publishing; 2022."},{"key":"936_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/002204261004000107","volume":"40","author":"LJ Liang","year":"2010","unstructured":"Liang LJ, Huang D, Brecht ML, Hser YI. Differences in mortality among heroin, cocaine, and methamphetamine users: a hierarchical bayesian approach. J Drug Issues. 2010;40:121\u201340.","journal-title":"J Drug Issues"},{"key":"936_CR29","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1111\/j.1360-0443.2007.01874.x","volume":"102","author":"S Kaye","year":"2007","unstructured":"Kaye S, McKetin R, Duflou J, Darke S. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction. 2007;102:1204\u201311.","journal-title":"Addiction"},{"issue":"64\u201371","key":"936_CR30","volume":"131","author":"HM Salihu","year":"2018","unstructured":"Salihu HM, Salemi JL, Aggarwal A, Steele BF, Pepper RC, Mogos MF, Aliyu MH. Opioid drug use and acute cardiac events among pregnant women in the United States. Am J Med. 2018;131(64\u201371): e61.","journal-title":"Am J Med"},{"key":"936_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.26544","volume":"5","author":"PT Korthuis","year":"2022","unstructured":"Korthuis PT, Cook RR, Foot CA, Leichtling G, Tsui JI, Stopka TJ, Leahy J, Jenkins WD, Baker R, Chan B, et al. Association of methamphetamine and opioid use with nonfatal overdose in rural communities. JAMA Netw Open. 2022;5: e2226544.","journal-title":"JAMA Netw Open"},{"key":"936_CR32","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1186\/s12889-022-14506-w","volume":"22","author":"H Palis","year":"2022","unstructured":"Palis H, Xavier C, Dobrer S, Desai R, Sedgemore KO, Scow M, Lock K, Gan W, Slaunwhite A. Concurrent use of opioids and stimulants and risk of fatal overdose: a cohort study. BMC Public Health. 2022;22:2084.","journal-title":"BMC Public Health"},{"key":"936_CR33","doi-asserted-by":"publisher","first-page":"E16","DOI":"10.5888\/pcd20.220316","volume":"20","author":"ME Saunders","year":"2023","unstructured":"Saunders ME, Humphrey JL, Lambdin BH. Spatiotemporal trends in three smoothed overdose death rates in US counties, 2012\u20132020. Prev Chronic Dis. 2023;20:E16.","journal-title":"Prev Chronic Dis"},{"key":"936_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2021.106950","volume":"120","author":"D Mustaquim","year":"2021","unstructured":"Mustaquim D, Jones CM, Compton WM. Trends and correlates of cocaine use among adults in the United States, 2006\u20132019. Addict Behav. 2021;120: 106950.","journal-title":"Addict Behav"},{"key":"936_CR35","doi-asserted-by":"publisher","first-page":"109946","DOI":"10.1016\/j.drugalcdep.2023.109946","volume":"249","author":"AA Jones","year":"2023","unstructured":"Jones AA, Shearer RD, Segel JE, Santos-Lozada A, Strong-Jones S, Vest N, Teixeira da Silva D, Khatri UG, Winkelman TNA. Opioid and stimulant attributed treatment admissions and fatal overdoses: using national surveillance data to examine the intersection of race, sex, and polysubstance use, 1992\u20132020. Drug Alcohol Depend. 2023;249:109946.","journal-title":"Drug Alcohol Depend"},{"key":"936_CR36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3711","volume":"3","author":"WC Goedel","year":"2020","unstructured":"Goedel WC, Shapiro A, Cerda M, Tsai JW, Hadland SE, Marshall BDL. Association of racial\/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States. JAMA Netw Open. 2020;3: e203711.","journal-title":"JAMA Netw Open"},{"key":"936_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234809","volume":"15","author":"C Ronsley","year":"2020","unstructured":"Ronsley C, Nolan S, Knight R, Hayashi K, Klimas J, Walley A, Wood E, Fairbairn N. Treatment of stimulant use disorder: a systematic review of reviews. PLoS ONE. 2020;15: e0234809.","journal-title":"PLoS ONE"},{"key":"936_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.evalprogplan.2008.09.003","volume":"32","author":"JC Marsh","year":"2009","unstructured":"Marsh JC, Cao D, Guerrero E, Shin HC. Need-service matching in substance abuse treatment: racial\/ethnic differences. Eval Program Plann. 2009;32:43\u201351.","journal-title":"Eval Program Plann"},{"key":"936_CR39","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1176\/appi.ajp.158.12.2027","volume":"158","author":"K Wells","year":"2001","unstructured":"Wells K, Klap R, Koike A, Sherbourne C. Ethnic disparities in unmet need for alcoholism, drug abuse, and mental health care. Am J Psychiatry. 2001;158:2027\u201332.","journal-title":"Am J Psychiatry"},{"key":"936_CR40","doi-asserted-by":"publisher","first-page":"493","DOI":"10.15288\/jsa.2006.67.493","volume":"67","author":"BM Booth","year":"2006","unstructured":"Booth BM, Leukefeld C, Falck R, Wang J, Carlson R. Correlates of rural methamphetamine and cocaine users: results from a multistate community study. J Stud Alcohol. 2006;67:493\u2013501.","journal-title":"J Stud Alcohol"},{"key":"936_CR41","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/10550490902787031","volume":"18","author":"LT Wu","year":"2009","unstructured":"Wu LT, Blazer DG, Patkar AA, Stitzer ML, Wakim PG, Brooner RK. Heterogeneity of stimulant dependence: a national drug abuse treatment clinical trials network study. Am J Addict. 2009;18:206\u201318.","journal-title":"Am J Addict"},{"key":"936_CR42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/15332640.2017.1325809","volume":"18","author":"KC Flynn","year":"2019","unstructured":"Flynn KC, Hoffer LD. Transitioning illicit drug preferences and emerging user identities in Ohio: the proliferation of methamphetamine use among African Americans. J Ethn Subst Abuse. 2019;18:67\u201388.","journal-title":"J Ethn Subst Abuse"},{"key":"936_CR43","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2105\/AJPH.2019.305527","volume":"110","author":"CM Jones","year":"2020","unstructured":"Jones CM, Olsen EO, O\u2019Donnell J, Mustaquim D. Resurgent methamphetamine use at treatment admission in the United States, 2008\u20132017. Am J Public Health. 2020;110:509\u201316.","journal-title":"Am J Public Health"},{"key":"936_CR44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1300\/J233v04n01_06","volume":"4","author":"RL Sexton","year":"2005","unstructured":"Sexton RL, Carlson RG, Siegal HA, Falck RS, Leukefeld C, Booth B. Barriers and pathways to diffusion of methamphetamine use among African Americans in the rural South: preliminary ethnographic findings. J Ethn Subst Abuse. 2005;4:77\u2013103.","journal-title":"J Ethn Subst Abuse"},{"key":"936_CR45","unstructured":"Ohio Department of Mental Health and Addiction Services (OhioMAS): Ohio substance abuse monitoring network: Surveillance of drug abuse trends in the state of Ohio: January-June 2016. Columbus, OH; 2016."},{"key":"936_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2021.106541","volume":"152","author":"RA Jenkins","year":"2021","unstructured":"Jenkins RA. The fourth wave of the US opioid epidemic and its implications for the rural US: a federal perspective. Prev Med. 2021;152: 106541.","journal-title":"Prev Med"},{"key":"936_CR47","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12954-023-00736-7","volume":"20","author":"MR Khan","year":"2023","unstructured":"Khan MR, Hoff L, Elliott L, Scheidell JD, Pamplin JR 2nd, Townsend TN, Irvine NM, Bennett AS. Racial\/ethnic disparities in opioid overdose prevention: comparison of the naloxone care cascade in White, Latinx, and Black people who use opioids in New York City. Harm Reduct J. 2023;20:24.","journal-title":"Harm Reduct J"},{"key":"936_CR48","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.2105\/AJPH.2022.306767","volume":"112","author":"AM Lopez","year":"2022","unstructured":"Lopez AM, Thomann M, Dhatt Z, Ferrera J, Al-Nassir M, Ambrose M, Sullivan S. Understanding racial inequities in the implementation of harm reduction initiatives. Am J Public Health. 2022;112:S173\u201381.","journal-title":"Am J Public Health"},{"key":"936_CR49","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.drugalcdep.2019.05.017","volume":"202","author":"M Pinedo","year":"2019","unstructured":"Pinedo M. A current re-examination of racial\/ethnic disparities in the use of substance abuse treatment: do disparities persist? Drug Alcohol Depend. 2019;202:162\u20137.","journal-title":"Drug Alcohol Depend"},{"key":"936_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102727","volume":"85","author":"MA Kolak","year":"2020","unstructured":"Kolak MA, Chen YT, Joyce S, Ellis K, Defever K, McLuckie C, Friedman S, Pho MT. Rural risk environments, opioid-related overdose, and infectious diseases: a multidimensional, spatial perspective. Int J Drug Policy. 2020;85: 102727.","journal-title":"Int J Drug Policy"},{"key":"936_CR51","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/QAI.0000000000001098","volume":"73","author":"MM Van Handel","year":"2016","unstructured":"Van Handel MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, Lewis B, Bohm MK, Jones CM, Flanagan BE, Siddiqi AE, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. J Acquir Immune Defic Syndr. 2016;73:323\u201331.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"936_CR52","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drugpo.2018.08.007","volume":"63","author":"NC Peiper","year":"2019","unstructured":"Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: Findings from a syringe services program in the Southeastern United States. Int J Drug Policy. 2019;63:122\u20138.","journal-title":"Int J Drug Policy"},{"key":"936_CR53","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/JAN.0000000000000230","volume":"29","author":"L Chimbar","year":"2018","unstructured":"Chimbar L, Moleta Y. Naloxone effectiveness: a systematic review. J Addict Nurs. 2018;29:167\u201371.","journal-title":"J Addict Nurs"},{"key":"936_CR54","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1192\/pb.bp.110.031831","volume":"35","author":"NM Petry","year":"2011","unstructured":"Petry NM. Contingency management: what it is and why psychiatrists should want to use it. Psychiatrist. 2011;35:161\u20133.","journal-title":"Psychiatrist"},{"key":"936_CR55","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1186\/s12889-022-14180-y","volume":"22","author":"D Neffa-Creech","year":"2022","unstructured":"Neffa-Creech D, Plant A, Montoya JA, Oruga R, Kilgore EA, Fraser R, Tesema L. Development and evaluation of a social marketing campaign to address methamphetamine use in Los Angeles County. BMC Public Health. 2022;22:1796.","journal-title":"BMC Public Health"},{"key":"936_CR56","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/10550887.2014.975610","volume":"34","author":"DM Herbeck","year":"2015","unstructured":"Herbeck DM, Brecht ML, Lovinger K. Mortality, causes of death, and health status among methamphetamine users. J Addict Dis. 2015;34:88\u2013100.","journal-title":"J Addict Dis"},{"key":"936_CR57","doi-asserted-by":"publisher","first-page":"5624","DOI":"10.2174\/092986712803988893","volume":"19","author":"I Riezzo","year":"2012","unstructured":"Riezzo I, Fiore C, De Carlo D, Pascale N, Neri M, Turillazzi E, Fineschi V. Side effects of cocaine abuse: multiorgan toxicity and pathological consequences. Curr Med Chem. 2012;19:5624\u201346.","journal-title":"Curr Med Chem"},{"key":"936_CR58","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1353\/sgo.2018.0022","volume":"58","author":"J Cordes","year":"2018","unstructured":"Cordes J. Spatial trends in opioid overdose mortality in North Carolina: 1999\u20132015. Southeast Geogr. 2018;58:193\u2013211.","journal-title":"Southeast Geogr"},{"key":"936_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.993507","volume":"10","author":"TC Yang","year":"2022","unstructured":"Yang TC, Shoff C, Choi SE, Sun F. Multiscale dimensions of county-level disparities in opioid use disorder rates among older Medicare beneficiaries. Front Public Health. 2022;10: 993507.","journal-title":"Front Public Health"},{"key":"936_CR60","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/003335491513000411","volume":"130","author":"S Slavova","year":"2015","unstructured":"Slavova S, O\u2019Brien DB, Creppage K, Dao D, Fondario A, Haile E, Hume B, Largo TW, Nguyen C, Sabel JC, et al. Drug overdose deaths: let\u2019s get specific. Public Health Rep. 2015;130:339\u201342.","journal-title":"Public Health Rep"},{"key":"936_CR61","doi-asserted-by":"publisher","first-page":"231","DOI":"10.23907\/2013.029","volume":"3","author":"M Warner","year":"2013","unstructured":"Warner M, Paulozzi LJ, Nolte KB, Davis GG, Nelson LS. State variation in certifying manner of death and drugs involved in drug intoxication deaths. Academ Forens Pathol. 2013;3:231\u20137.","journal-title":"Academ Forens Pathol"},{"key":"936_CR62","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jamapsychiatry.2022.0004","volume":"79","author":"JR Friedman","year":"2022","unstructured":"Friedman JR, Hansen H. Evaluation of increases in drug overdose mortality rates in the US by race and ethnicity before and during the COVID-19 pandemic. JAMA Psychiat. 2022;79:379\u201381.","journal-title":"JAMA Psychiat"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00936-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-00936-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00936-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T12:08:56Z","timestamp":1705493336000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-00936-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["936"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-00936-9","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,17]]},"assertion":[{"value":"12 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}